Navigation Links
23andMe and ALSPAC identify 16 new genetic associations for pollen, dust-mite and cat allergies
Date:7/2/2013

Mountain View, Calif. The largest genome-wide association study ever conducted on common allergies, including pollen, dust-mite and cat allergies, has identified 16 new genetic associations related to the condition. The study, conducted in collaboration between 23andMe, the leading personal genetics company, and the Avon Longitudinal Study of Parents and Children (ALSPAC), examined data for more than 53,000 individuals. The study also identified eight genetic variations for allergies that have previously been associated with asthma. Genes implicated in the study highlight a series of key pathways in the biological basis of common allergies.

Allergies and allergic asthma are among the most common diseases in the industrialized world. In the United States, a 2005 survey showed that more than half of the population tested positive for sensitization to at least one of 10 common allergens, a considerable increase over results of the same survey performed approximately 10 years earlier.[i]

"We've seen some substantial increases in prevalence of allergies and asthma," said David Hinds, Ph.D., author and 23andMe principal scientist. "Although environmental factors certainly play a role, our study reinforces the genetic link between common allergens and a person's susceptibility to experiencing an allergic reaction. Additionally, current estimates of the heritability of allergies are high, which suggests that understanding the genetic factors underlying allergic conditions may be key to understanding who might be most likely to suffer from allergies and how the condition might best be treated."

The study, titled "A Genome-Wide Association Meta-Analysis of Self-Reported Allergy Identifies Shared and Allergy-Specific Susceptibility Loci" was published online on June 30, 2013 in Nature Genetics, a leading monthly, international scientific journal.

23andMe selected three common self-reported allergy phenotypes pollen, dust-mi
'/>"/>

Contact: Kendra Brogden
kbrogden@wcgworld.com
415-658-9765
23andMe Inc.
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. 23andMe identifies multiple genetic factors impacting development of nearsightedness
2. 23andMes Ancestry Composition reveals peoples ancestral origins going back 500+ years
3. 23andMe scientists receive more than $500,000 in National Institutes of Health funding
4. 23andMe Names Christine Castro, Neil Rothstein and Jonathan Ward to Leadership Positions
5. 23andMe opens its API to developers
6. 23andMe contributes to genetic discoveries related to male pattern baldness
7. 23andMe identifies 5 significant genetic associations for hypothyroidism
8. Scientists identify promising antiviral compounds
9. NIH to fund collaborations with industry to identify new uses for existing compounds
10. Study helps managers identify regions with multiple threat potential, including wildfires
11. Iris Biometrics Leader EyeLock Joins the FIDO Alliance to Help Identify More Secure Replacement for Usernames and Passwords
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... Building on earlier pioneering work by researchers at ... consortium of university researchers has produced the most ... Scientists could use the model, known as Recon ... for diseases like cancer, diabetes and even psychiatric ...
... identified seven new genetic regions associated with age-related macular ... individuals. The findings, reported online March 3 in ... and therapeutic targets for AMD., The AMD Gene Consortium, ... National Eye Institute, also confirmed 12 genetic loci identified ...
... in the journal Science reveals a decline in ... The study could not have been conducted without the work ... research., Charles Robertson, a self-taught entomologist who studied zoology and ... one of the first scientists to make detailed records of ...
Cached Biology News:International consortium builds 'Google Map' of human metabolism 2International consortium builds 'Google Map' of human metabolism 3International consortium builds 'Google Map' of human metabolism 4Genetic risk factors for common eye disorder come into focus 2Illinois town provides a historical foundation for today's bee research 2
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... 26, 2015 After litigating and negotiating ... relating to P2i United States patent ... in the United States without any ... of either party. As a result of the parties, settlement, ... California dismissed the case without prejudice. ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... (Nasdaq: MITI ), a biopharmaceutical company developing ... and autoimmune diseases, today announced that it is regaining ... to its most advanced BiTE antibody candidate, blinatumomab, also ... phase 2 clinical trial with blinatumomab for the treatment ...
... outstanding shares of Genentech for US$95.00 per share ... as an independent center; South San Francisco site ... Genentech,s unique culture to be maintained-- Innovation will ... and sharing of IP, technologies, partnerships and other ...
... Breweries announced a new partnership, which will create a joint venture ... , ... Lexington, KY (Vocus) March 11, 2009 -- ... announced a new partnership, which will create a joint venture company ...
Cached Biology Technology:Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 2Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 3Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 4Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 5Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 6Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation 7Alltech, Mitsui and Asahi Breweries Create New Venture 2Alltech, Mitsui and Asahi Breweries Create New Venture 3
... SeeDNA co-precipitant, 250 ul ... color ensures easy pellet ... acid recovery.Chemically inert, compatible ... applications.Simple 5-minute protocol. Category: ...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Recombinant Mouse sTNF RII/TNFRSF1B...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: